Elder G H, Lee G B, Tovey J A
N Engl J Med. 1978 Aug 10;299(6):274-8. doi: 10.1056/NEJM197808102990603.
To investigate the role of uroporphyrinogen decarboxylase in the pathogenesis of the sporadic form of porphyria cutanea tarda, we measured this enzyme in liver, erythrocytes and cultured skin fibroblasts, and also measured coproporphyrinogen oxidase and the total iron concentration in liver. The mean uroporphyrinogen decarboxylase activity was lower in liver from seven male patients (9.0 pmol of coproporphyrin per minute per milligram of protein) than in 12 controls, including seven with alcoholic liver disease (22.3 pmol per minute per milligram; P less than 0.05). Coproporphyrinogen oxidase activities were the same in each group. Liver iron concentrations were lower during remission, but uroporphyrinogen decarboxylase activities were not related to clinical activity for uroporphyrin excretion. Erythrocyte and fibroblast enzyme activities were the same as in normal subjects. A hepatic uroporphyrinogen decarboxylase defect is a prerequisite for the development of porphyria cutanea tarda, but other factors, which probably do not alter uroporphyrinogen decarboxylase activity, determine the clinical onset. In sporadic porphyria cutaneous tarda, the enzyme defect appears to be restricted to the liver.
为了研究尿卟啉原脱羧酶在迟发性皮肤卟啉症散发型发病机制中的作用,我们测定了肝脏、红细胞及培养的皮肤成纤维细胞中的该酶活性,同时还测定了肝脏中的粪卟啉原氧化酶活性及总铁浓度。7例男性患者肝脏中的尿卟啉原脱羧酶平均活性(每分钟每毫克蛋白质生成9.0皮摩尔粪卟啉)低于12例对照者,其中包括7例酒精性肝病患者(每分钟每毫克蛋白质生成22.3皮摩尔;P<0.05)。每组的粪卟啉原氧化酶活性相同。缓解期肝脏铁浓度较低,但尿卟啉原脱羧酶活性与尿卟啉排泄的临床活动度无关。红细胞和成纤维细胞中的酶活性与正常受试者相同。肝脏尿卟啉原脱羧酶缺陷是迟发性皮肤卟啉症发病的先决条件,但其他因素(可能不改变尿卟啉原脱羧酶活性)决定临床发病。在迟发性皮肤卟啉症散发型中,酶缺陷似乎仅限于肝脏。